Impact of Co‐Morbid Immunocompromise in HPV ‐Associated Oropharyngeal Squamous Cell Carcinoma
The Laryngoscope · 2026
DOI: 10.1002/lary.70584 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2026. Verfasst von Maxwell L Weng und 7 weiteren Autor:innen. Beteiligte Einrichtung: David Geffen School of Medicine at UCLA, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Immunocompromised Host, Oropharyngeal Neoplasms, Papillomavirus Infections, Human Papillomavirus Viruses. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
To characterize the survival and morbidity associated with immunocompromised status in patients with surgically resected Human Papillomavirus positive oropharyngeal squamous cell carcinoma (HPV + OPSCC).
Methods
We reviewed patients with surgically resected HPV + OPSCC at a tertiary institution between 2000 and 2023. The survival and morbidity associated with an immunocompromised status were assessed with multivariable Cox proportional hazards models controlling for patient, tumor, and treatment characteristics.
Results
Among 278 patients with HPV+ OPSCC that met inclusion criteria, 14 patients were immunocompromised. Causes of immunocompromise: 4, leukemia or lymphoma; 3, organ transplantation; 3, medically immunosuppressed; 2, HIV; 2, myelodysplastic syndrome and pancytopenia. Adjusting for covariates, the immunocompromised patient group had significantly worse overall survival (64.3% vs. 91.7%; HR 4.12, 95% CI: 1.14–14.90, p < 0.005) compared to the non‐compromised group. The immunocompromised patient group did not have a significantly different postoperative length of stay (3.96 vs. 3.5 days; aβ 0.66, 95% CI: −1.30 to 2.64).
Conclusions
In this small, heterogeneous cohort of surgically resected HPV + OPSCC, immunocompromised status was associated with significantly worse overall survival; however, these exploratory findings should be interpreted cautiously. Level of Evidence 3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
- Department of Head & Neck Surgery, David Geffen School of Medicine, Los Angeles, California, USA.
- Department of Otolaryngology-Head and Neck Surgery, Stanford University, Palo Alto, California, USA.
- Department of Pathology, David Geffen School of Medicine, Los Angeles, California, USA.
- Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Maxwell L Weng, Song Hon Hwang, Maie A St John
Zitieren
APA
Weng, M. L., Vitkovska, T., Hwang, S. H., Evans, L. K., Yang, H. H., Dann, C., Sajed, D., & St John, M. A. (2026). Impact of Co‐Morbid Immunocompromise in HPV ‐Associated Oropharyngeal Squamous Cell Carcinoma. The Laryngoscope. https://doi.org/10.1002/lary.70584
Vancouver
Weng ML, Vitkovska T, Hwang SH, Evans LK, Yang HH, Dann C, et al. Impact of Co‐Morbid Immunocompromise in HPV ‐Associated Oropharyngeal Squamous Cell Carcinoma. The Laryngoscope. 2026. doi:10.1002/lary.70584
BibTeX
@article{Weng2026,
author = {Weng, Maxwell L and Vitkovska, Tereza and Hwang, Song Hon and Evans, Lauran K and Yang, Hong-Ho and Dann, Christopher and Sajed, Dipti and St John, Maie A},
title = {Impact of Co‐Morbid Immunocompromise in HPV ‐Associated Oropharyngeal Squamous Cell Carcinoma},
journal = {The Laryngoscope},
year = {2026},
doi = {10.1002/lary.70584}
}
EUVIMED